Free Trial

Omnicell (OMCL) Stock Price, News & Analysis

Omnicell logo
$28.69 -1.08 (-3.63%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$28.70 +0.00 (+0.02%)
As of 07/11/2025 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Omnicell Stock (NASDAQ:OMCL)

Key Stats

Today's Range
$28.68
$29.49
50-Day Range
$24.63
$31.68
52-Week Range
$22.66
$55.75
Volume
255,198 shs
Average Volume
563,106 shs
Market Capitalization
$1.34 billion
P/E Ratio
62.37
Dividend Yield
N/A
Price Target
$44.83
Consensus Rating
Moderate Buy

Company Overview

Omnicell Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

OMCL MarketRank™: 

Omnicell scored higher than 70% of companies evaluated by MarketBeat, and ranked 311th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Omnicell has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Omnicell has only been the subject of 4 research reports in the past 90 days.

  • Read more about Omnicell's stock forecast and price target.
  • Earnings Growth

    Earnings for Omnicell are expected to grow by 13.76% in the coming year, from $1.09 to $1.24 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Omnicell is 62.37, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.90.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Omnicell is 62.37, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.96.

  • Price to Book Value per Share Ratio

    Omnicell has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Omnicell's valuation and earnings.
  • Percentage of Shares Shorted

    4.73% of the float of Omnicell has been sold short.
  • Short Interest Ratio / Days to Cover

    Omnicell has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Omnicell has recently decreased by 12.20%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Omnicell does not currently pay a dividend.

  • Dividend Growth

    Omnicell does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.73% of the float of Omnicell has been sold short.
  • Short Interest Ratio / Days to Cover

    Omnicell has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Omnicell has recently decreased by 12.20%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Omnicell has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Omnicell this week, compared to 6 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Omnicell insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.52% of the stock of Omnicell is held by insiders.

  • Percentage Held by Institutions

    97.70% of the stock of Omnicell is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Omnicell's insider trading history.
Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

OMCL Stock News Headlines

3 Cash-Heavy Stocks Facing Headwinds
Utah’s New Oil Find
The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake.
Omnicell CFO Nchacha Etta to Step Down
What Analysts Are Saying About Omnicell Stock
See More Headlines

OMCL Stock Analysis - Frequently Asked Questions

Omnicell's stock was trading at $44.52 at the beginning of the year. Since then, OMCL shares have decreased by 35.6% and is now trading at $28.69.

Omnicell, Inc. (NASDAQ:OMCL) announced its earnings results on Tuesday, May, 6th. The company reported $0.26 EPS for the quarter, topping analysts' consensus estimates of $0.16 by $0.10. Omnicell's quarterly revenue was up 9.5% on a year-over-year basis.
Read the conference call transcript
.

Omnicell subsidiaries include these companies: MarkeTouch Media LLC, ReCept Pharmacy, FDS Amplicare, 340B Link Business, InPharmics, Ateb Inc., Aesynt, and more.

Top institutional shareholders of Omnicell include Assenagon Asset Management S.A. (0.02%) and Diversified Trust Co (0.02%). Insiders that own company stock include Randall A Lipps, Peter J Kuipers, Mark W Parrish, Scott Peter Seidelmann, Joanne B Bauer and Christine Marie Mellon.
View institutional ownership trends
.

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Omnicell investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
5/06/2025
Today
7/12/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Health Care Technology
Current Symbol
NASDAQ:OMCL
CIK
926326
Employees
3,670
Year Founded
1992

Price Target and Rating

High Price Target
$64.00
Low Price Target
$34.00
Potential Upside/Downside
+56.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.46
Trailing P/E Ratio
62.37
Forward P/E Ratio
26.32
P/E Growth
N/A
Net Income
$12.53 million
Net Margins
1.87%
Pretax Margin
2.98%
Return on Equity
4.60%
Return on Assets
2.56%

Debt

Debt-to-Equity Ratio
0.13
Current Ratio
1.38
Quick Ratio
1.23

Sales & Book Value

Annual Sales
$1.11 billion
Price / Sales
1.21
Cash Flow
$2.95 per share
Price / Cash Flow
9.73
Book Value
$26.84 per share
Price / Book
1.07

Miscellaneous

Outstanding Shares
46,840,000
Free Float
45,664,000
Market Cap
$1.34 billion
Optionable
Optionable
Beta
0.76

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:OMCL) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners